Chinese expert guidance on critical care hemoadsorption (2025)

Hemoadsorption (HA) has become an important adjunctive therapy in critical care, with potential benefits in managing sepsis, severe acute pancreatitis (SAP), poisoning, and rhabdomyolysis (RM). However, significant heterogeneity in clinical evidence, the diversity of adsorption devices, and lack of standardized protocols hinder its widespread and rational use. To address these issues, the Critical Care Nephrology Quality Control Subcommittee of the National Center for Healthcare Quality Management in Critical Care Medicine convened a multidisciplinary expert panel to develop a national consensus. This expert consensus summarizes current evidence, defines core concepts, categorizes HA materials and modes, and outlines indications, timing, operational procedures, anticoagulation strategies, and safety considerations. It also provides expert recommendations for the use of HA in various clinical scenarios based on collective clinical experience and literature review. The aim is to promote standardized, safe, and effective HA practices across critical care settings in China.